Subscriber access provided by UNIVERSITY OF LEEDS
Article
Neonatal Metabolomic Profiles Related to Prenatal Arsenic Exposure Jessica Evelyn Laine, Kathryn A Bailey, Andrew F. Olshan, Lisa Smeester, Zuzana Drobna, Miroslav Stýblo, Christelle Douillet, Gonzalo García-Vargas, Marisela RubioAndrade, Wimal W Pathmasiri, Susan L McRitchie, Susan J. Sumner, and Rebecca C Fry Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.6b04374 • Publication Date (Web): 02 Dec 2016 Downloaded from http://pubs.acs.org on December 10, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Environmental Science & Technology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 35
Environmental Science & Technology
1
Neonatal Metabolomic Profiles Related to
2
Prenatal Arsenic Exposure
3 4 5 6 7
Jessica E. Laine‡, Kathryn A. Bailey†, Andrew F. Olshan‡, Lisa Smeester†, Zuzana Drobná§, Miroslav Stýblo┴, Christelle Douillet┴, Gonzalo García-Vargas║, Marisela Rubio-Andrade║, Wimal Pathmasiriϕ, Susan McRitchieϕ, Susan J. Sumnerϕ and Rebecca C. Fry†*
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
‡
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, 27599, USA † Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, 27599, USA. § Department of Biological Sciences, College of Sciences, North Carolina State University, Raleigh, North Carolina, 27695, USA. ┴ Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, 27599, USA. ║ Facultad de Medicina, Universidad Juarez del Estado de Durango, Gómez Palacio, Durango, 35050, Mexico. ϕ RTI International, Research Triangle Park, North Carolina, 27709, USA.
Short title: Arsenic and the neonate metabolome
ACS Paragon Plus Environment
1
Environmental Science & Technology
24 25 26
Page 2 of 35
ABSTRACT
27
Prenatal inorganic arsenic (iAs) exposure is associated with health effects evident
28
at birth and later in life. An understanding of the relationship between prenatal iAs
29
exposure and alterations in the neonatal metabolome could reveal critical molecular
30
modifications, potentially underpinning disease etiologies. In this study, nuclear magnetic
31
resonance (NMR) spectroscopy-based metabolomic analysis was used to identify
32
metabolites in neonate cord serum associated with prenatal iAs exposure in participants
33
from the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort, in Gómez
34
Palacio, Mexico. Through multivariable linear regression, ten cord serum metabolites
35
were identified as significantly associated with total urinary iAs and/or iAs metabolites,
36
measured as %iAs, %monomethylated arsenicals (MMAs) and %dimethylated arsenicals
37
(DMAs). A total of seventeen metabolites were identified as significantly associated with
38
total iAs and/or iAs metabolites in cord serum. These metabolites are indicative of
39
changes in important biochemical pathways such as vitamin metabolism, the citric acid
40
(TCA) cycle, and amino acid metabolism. These data highlight that maternal
41
biotransformation of iAs and neonatal levels of iAs and its metabolites are associated
42
with differences in neonate cord metabolomic profiles. The results demonstrate the
43
potential utility of metabolites as biomarkers/indicators of in utero environmental
44
exposure.
45
ACS Paragon Plus Environment
2
Page 3 of 35
Environmental Science & Technology
46 47 48
INTRODUCTION
49
in their drinking water that have been linked to chronic diseases such as precancerous
50
skin lesions, cardiovascular disease, peripheral vascular disease, diabetes mellitus,
51
hypertension, and cancers of the urinary bladder, skin, lung, and liver.1-3 Exposure to iAs
52
during periods of increased susceptibility, including in utero and early childhood, is of
53
particular concern. Early-life iAs exposure is associated with both short- and long-term
54
adverse health effects including increased risk for preterm birth, low birth weight, infant
55
mortality, childhood neurological impairments, susceptibility to infectious disease, and
56
chronic disease development later in life, including cancer.4
Millions of individuals worldwide are exposed to levels of inorganic arsenic (iAs)
57
A precise mechanistic basis for the relationship between prenatal iAs exposure
58
and disease has not been elucidated and is likely multi-factorial. Potential mechanisms
59
for iAs-associated diseases include the induction of oxidative stress, enzyme inhibition,
60
interference with DNA repair, chromosomal aberrations, and perturbation of cell
61
signaling pathways, and epigenetic instability.5 Specific to prenatal iAs exposure,
62
previous studies have highlighted changes in fetal gene expression,6-8 fetal leukocyte
63
DNA methylation,7-10 and increased protein signaling of inflammatory mediators in cord
64
serum.11 In spite of these advances, much remains unknown about the biochemical
65
mechanisms underlying the health effects associated with prenatal iAs exposure.
66
One factor known to influence the susceptibility to iAs-associated diseases is an
67
individual’s efficiency of iAs biotransformation/metabolism. Arsenic is biotransformed
68
in humans to produce monomethylated arsenicals (MMAs) and dimethylated arsenicals
69
(DMAs) that can exist in either a trivalent (+3) or pentavalent (+5) oxidation state.
ACS Paragon Plus Environment
3
Environmental Science & Technology
Page 4 of 35
70
Specifically, six major arsenicals associated with iAs exposure have been detected in
71
human urine, namely arsenite (iAsIII), arsenate (iAsV), monomethylarsonous acid
72
(MMAIII), monomethylarsonic acid (MMAV), dimethylarsinous acid (DMAIII), and
73
dimethylarsinic acid (DMAV).12, 13 High urinary proportions of MMAs/total arsenic and
74
increased MMAs/DMAs are likely indicators of inefficient iAs biotransformation.
75
Inefficient biotransformation (or methylation) of iAs, as indicated by higher proportions
76
of MMAs in urine, has been associated with the development of several adverse
77
outcomes in humans including urinary bladder cancer, non-melanoma skin cancers,
78
carotid atherosclerosis, and chromosomal aberrations (reviewed in14). In recent work, we
79
have shown that elevated levels and proportions of MMAs in maternal urine are
80
associated with decreases in placental weight and fetal birth weight.15
81
There are an increasing number of system-wide methodologies available to
82
provide insight into mechanisms underlying environmentally-mediated disease, including
83
metabolomics. Metabolomics involves the analysis of the low molecular weight
84
metabolites in cells, tissues, and biological fluids, providing a profile of the biochemistry
85
and end result of multiple enzymatic processes, or the “metabotype,” of an individual.
86
Metabolomic profiling has been used to study the impacts of nutritional, pharmaceutical,
87
and environmental toxicant exposures.16 Metabolomic profiling is an ideal tool for
88
biomarker assessment as it is efficient and relatively noninvasive, and it can convey
89
information
90
identified in both maternal and fetal-health studies have been associated with fetal
91
malformations, preterm delivery, premature rupture of membranes, gestational diabetes
about
disease/physiologic
phenotypes.17,18
ACS Paragon Plus Environment
Metabolomic
biomarkers
4
Page 5 of 35
Environmental Science & Technology
92
mellitus, preeclampsia, low birth weight, and hypoxic-ischemic encephalopathy- all
93
representing adverse outcomes that are relevant to iAs exposure.19
94
Recent developments in metabolomic technologies and statistical methodologies
95
have allowed for explorations for global changes in biological systems, predictive
96
modeling of metabolomics alterations, and the use of metabolomics in clinical
97
applications in regards to various exposures and/or disease states. Specifically, the use of
98
nuclear magnetic resonance (NMR) spectroscopy to quantify and determine the
99
metabotype of an individual or a population provides an excellent tool for detection of
100
metabolites in ways that are non-biased, easily quantifiable, require little to no
101
separation- all allowing for the identification of novel compounds that are less tractable
102
to GC-MS or LC-MS analysis.20 Additionally, a NMR-based metabolomic approach is
103
particularly beneficial for human samples that may not be easily attainable or are limited
104
in supply, as it is a non-destructive method that enables preservation of the sample and
105
analytes for subsequent analyses.21 NMR spectroscopy, combined with multivariable
106
statistical analysis, can be a powerful tool to detect metabolic changes induced by very
107
low doses of an exposure based on over- or underexpression of endogenous molecules.
108
Previous work has demonstrated the validity of NMR methods for populations exposed to
109
iAs.22
110
We recently identified differences in the levels of 132 human urinary metabolites
111
associated with iAs exposure in adults.23 Specifically, 59 metabolites that play a role in
112
tricarboxylic acid cycle and amino acid metabolism in diabetics were identified. Building
113
upon our understanding of the relationship between iAs exposure and the metabolome,
114
the aim of the present study was to identify a potential metabolomics signature of in utero
ACS Paragon Plus Environment
5
Environmental Science & Technology
Page 6 of 35
115
iAs exposure in cord serum using samples from the Biomarkers of Exposure to ARsenic
116
(BEAR) prospective pregnancy cohort in Gómez Palacio, Mexico.15 Investigations of the
117
metabolome of individuals exposed prenatally to iAs have not been previously
118
investigated. The pregnant women in this cohort lived in areas with elevated iAs in their
119
drinking water (up to 236 µg As/L, mean of 24.6 µg As/L).15 Several indicators of in
120
utero iAs exposure were used, including the sum of iAsIII and iAsV in maternal urine (U-
121
iAs), the sum of MMAIII and MMAV (U-MMAs), the sum of DMAIII and DMAV (U-
122
DMAs), and the sum of U-iAs, U-MMAs, and U-DMAs as total As in maternal urine (U-
123
tAs). As the efficiency of iAs metabolism has been linked to disease status, we set out to
124
determine whether there was a relationship between metabolite patterns in cord serum
125
and maternal iAs metabolism efficiency. Additionally, as a measurement of neonatal
126
levels of iAs we analyzed total cord serum arsenic (C-tAs) and/or iAs metabolites in cord
127
serum (C-iAs, C-MMAs, and/or C-DMAs). Using a quantitative metabolomics approach
128
coupled with multiple regression analyses, we identified metabolites altered in cord
129
serum that are significantly associated with prenatal iAs exposure and/or its methylated
130
metabolites.
131 132
ACS Paragon Plus Environment
6
Page 7 of 35
Environmental Science & Technology
133
MATERIALS AND METHODS
134 135
Subcohort Selection
136
The BEAR cohort has been described previously.15 Briefly, women were recruited
137
prior to the time of delivery from the time frame of August 2011 to March 2012 at the
138
General Hospital of Gómez Palacio. All procedures associated with this study were
139
approved by the Institutional Review Boards of Universidad Juárez del Estado de
140
Durango (UJED), Gómez Palacio, Durango, Mexico, and the University of North
141
Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, U.S.A. In the present study,
142
a subset of 50 cord serum samples were selected from the larger BEAR cohort that
143
spanned a range of iAs exposure where drinking water had variable levels of iAs. These
144
samples have been previously described as they were prioritized for other
145
molecular/mechanistic investigations, including assessment of iAs-associated microRNA
146
expression,24 DNA methylation,8 gene expression,8, 24 and protein expression.25
147
Methods for the measurements of iAs levels in this cohort have been previously
148
described.15 Briefly, the assessment of the levels of iAs in drinking water included
149
samples from the study participants’ home of their primary source of drinking water was
150
collected by the research team within four weeks of delivery. Maternal spot urine samples
151
were collected at the time of delivery, immediately transferred to cryovials and placed in
152
liquid nitrogen until and stored at -80oC until further processing.
153
Arsenical levels in maternal urine have been used as indicators of prenatal iAs
154
exposure.15,
26
155
HG-AAS with cryotrapping (CT) as described previously.27-29 The LODs for U-iAs, U-
156
MMAs, and U-DMAs were 0.2, 0.1, and 0.1 µg As/L, respectively. U-tAs was
Concentrations of U-iAs, U-MMAs, and U-DMAs were determined by
ACS Paragon Plus Environment
7
Environmental Science & Technology
Page 8 of 35
157
determined by summing U-iAs, U-MMAs and U-DMAs. To account for differences in
158
water intake/differential hydration, concentrations of U-iAs, U-MMAs, and U-DMAs in
159
each urine sample were adjusted using the following equation: iAs x (mean SG-
160
1)/(individual SG-1) as previously described.30 The efficiency of iAs biotransformation
161
was determined by calculating the proportions of the individual arsenicals iAs, MMAs,
162
and DMAs relative to total urinary As for each study subject. Metabolism efficiency for
163
iAs in maternal urine was determined by calculating the percentage of the individual
164
metabolites out of the total (U-%iAs, U-%MMAs, and U-%DMAs).
165
Cord blood was collected immediately after newborn delivery using an
166
anticoagulant-free vacutainer tube. Following clot formation, the tube was centrifuged at
167
177.1 g-force and the serum was collected and stored at -80°C until aliquots were shipped
168
on dry ice to UNC-Chapel Hill, NC, where they were immediately stored at -80oC.
169
Concentrations of cord serum arsenic included the measurement of cord serum-analyzed
170
iAs (C-iAs), MMAs (C-MMAs), and DMAs (C-DMAs) were determined using HG-CT-
171
ICP-MS as described previously.28, 31 The LODs for C-iAs, C-MMAs, and C-DMAs were
172
1.45, 0.06, and 0.12 pg As/mL, respectively. C-tAs was determined by summing C-iAs,
173
C-MMAs and C-DMAs. The percentages of the individual metabolites were calculated
174
relative to the total (C-%iAs, C-%MMAs, and C-%DMAs).
175
A certified standard reference material, Arsenic Species in Frozen Human Urine
176
(SRM 2669; National Institute of Standards and Technology) was used to assure accuracy
177
of iAs speciation analysis. Here, aliquots of SRM were diluted in urine or serum from an
178
unexposed subject and analyzed by HG-CT-AAS and HG-CT-ICP-MS, respectively. The
179
concentrations of iAs species in SRM in urine (after deduction of background iAs)
ACS Paragon Plus Environment
8
Page 9 of 35
Environmental Science & Technology
180
ranged from 88% to 105% of the certified values (105% for iAs, 88% for MMAs, 99%
181
for DMAs); the concentrations of iAs species in SRM in serum ranged from 85% to 90%
182
of the certified value (85% for iAs, 90% for MMAs, and 87% for DMAs).
183 184
1
H NMR Spectroscopy
185
The 50 cord serum samples were analyzed using nuclear magnetic resonance
186
(NMR) spectroscopy to identify neonatal metabolites that were associated with maternal
187
urinary arsenicals. Sample preparation, data acquisition, and data analysis followed
188
procedures previously described.32-35 Each of the 50 samples were processed individually,
189
whereby 150 µl of serum was prepared by adding 50 µl of 0.9% NaCl solution containing
190
4mM sodium formate (Chemical Shift Indicator) and 0.2% NaN3 (to inhibit bacterial
191
growth) in D2O. Each 200µl sample was then vortexed for 30 seconds and transferred
192
into 3mm NMR tubes (Bruker Bio-Spin, Germany).
193
1
H NMR spectra of serum samples were acquired on a Bruker Avance III 950
194
MHz NMR spectrometer (located at the David H. Murdock Research Institute at
195
Kannapolis, NC, USA) using a 5 mm cryogenically cooled ATMA inverse probe and
196
ambient temperature of 25℃. A CPMG pulse sequence with presaturation (cpmgpr1d)
197
was used for data acquisition. For each sample, 256 transients were collected into 32k
198
data points using a spectral width of 19.5 kHz (20.5 ppm), 2 s relaxation delay, 400 µs
199
fixed echo time, loop for T2 filter (l4)=80, and an acquisition time of 1.678 s per FID.
200
The water resonance was suppressed using resonance irradiation during the relaxation
201
delay. NMR spectra were processed using TopSpin software (Bruker, Germany). Spectra
202
were zero filled, and Fourier-transformed after exponential multiplication with line
ACS Paragon Plus Environment
9
Environmental Science & Technology
Page 10 of 35
203
broadening factor of 0.5. Phase and baseline of the spectra were manually corrected for
204
each spectrum. Spectra were referenced internally to the formate signal. The quality of
205
each NMR spectrum was assessed for the level of noise and alignment of identified
206
markers. In addition, quality control (QC) pooled samples were prepared using small
207
aliquots of each study sample by combining 12 µl aliquots into eppendorf tubes. Using a
208
quality control (QC) procedure described by Chan and co-workers,36 pooled samples
209
were prepared using aliquots of each study sample. Principal component analysis was
210
performed to determine that sufficient separation of the data occurred. These QC samples
211
were processed identically to each of the study samples.
212
Metabolites were identified and the relative metabolite concentrations were
213
determined prior to data analysis. This deconvolution of NMR peaks into metabolites and
214
relative quantification of these identified metabolites are advantageous over traditional
215
binning method in pattern recognition methods and identifying statistically significant
216
changes of metabolites.37, 38 A targeted profiling approach was carried out to identify the
217
metabolites. Metabolites were modeled using peak centers and splitting patterns of peaks
218
(J-coupling) from the NMR spectra, signals were matched by the analyst to the 36
219
metabolites identified using the library in Chenomx NMR Suite 8.1 Professional software
220
(Chenomx, Edmonton, Alberta, Canada). This software contains an internal library
221
adjustment for increments in chemical shift based on pH variation.38 Concentration
222
determinations for metabolites were established using relative integration of the analyte
223
to the formate internal standard. The library of concentrations was developed to account
224
for differences in integral values as related to the relaxation time of the signal.38
225
ACS Paragon Plus Environment
10
Page 11 of 35
226
Environmental Science & Technology
Statistical Analyses
227
Spearman rank correlations between maternal urinary and cord serum arsenicals
228
were calculated. Multivariable linear regression was used to determine the relationship
229
between U-tAs, U-%iAs, U-%MMAs, and U-%DMAs C-tAs, C-%iAs, C-%MMAs, or
230
C-%DMAs and the Chenomx concentration-matched metabolites using SAS 9.4 (SAS
231
Institute Inc, Cary, NC). Potential confounders were identified a priori based on their
232
known or potential association with both the exposure (iAs or its methylated metabolites)
233
and the outcome (cord serum metabolite levels). All models were adjusted for maternal
234
age (continuous), gender of the infant (male/female), and gestational age (continuous). To
235
improve model fit U-tAs and C-tAs were was natural log transformed. Regression
236
assumptions of linearity and the homogeneity of residuals were evaluated by examination
237
of appropriate residual plots. A false discovery rate (FDR) correction was calculated for
238
all p-values to account for multiple comparisons, with significance set at the acceptable
239
level of q< 0.20.23, 39, 40 The identified cord serum metabolites that were significantly
240
associated with U-tAs and/or the indicators for iAs biotransformation/metabolism
241
efficiency indicators (U-%iAs, U-%MMAs, and U-%DMAs) and for cord serum total
242
arsenic (C-tAs) and/or percentages of iAs in cord serum (C-%iAs, C-%MMAs, and/or C-
243
%DMAs) were then analyzed for enriched pathways, using MetaboAnalyst.41
244
Significance was set at p